Aviado · Research
Longevity Daily
Monday, June 29, 2026
Listen
Today's Brief
Today's strongest stories converge on brain health and longevity interventions. The lead story makes a compelling case that getting the Shingrix vaccine is one of the most evidence-backed steps you can take to prevent dementia—while a new NeurologyLive analysis raises a counterintuitive flag on metformin's possible link to increased neurodegenerative risk at high doses. The NYT weighs in on whether GLP-1 drugs like Ozempic could actually slow biological aging. Aviado's krill oil breakdown rounds out the issue with something rare: a supplement where your personal response is directly measurable in 12 weeks.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Shingles Triggers Brain Inflammation—And the Vaccine That May Stop It From Causing Dementia
Shingles infection causes direct inflammation in the brain, and a growing body of research now links this mechanism to accelerated cognitive decline. Multiple studies connect shingles vaccination—particularly Shingrix, the newer recombinant vaccine approved in 2017—to meaningfully reduced dementia risk, with experts noting the newer vaccine appears to offer comparable neuroprotection to its predecessor. The practical takeaway is unusually direct: if you're over 50, getting vaccinated isn't just about avoiding a painful rash—it may be one of the most evidence-backed, underutilized steps available for protecting long-term brain health.
Read more →Does Metformin Raise Dementia Risk? New Evidence Challenges Its Longevity Status
Metformin is widely discussed in longevity circles as a candidate anti-aging drug—but new evidence suggests a troubling signal at high doses and long-term use: an association with increased risk of neurodegenerative disease and dementia. This doesn't definitively overturn metformin's potential benefits, but it's a significant flag for anyone using it off-label for longevity purposes. If you're on metformin, this is worth bringing to your physician, particularly regarding dose and duration.
Read more →A 1,500-Patient Alzheimer's Trial Is Approaching Its 2026 Readout
POLARIS-AD—a phase 3, double-blind, placebo-controlled trial of AR1001 (mirodenafil) enrolling over 1,500 patients with mild cognitive impairment or early Alzheimer's disease—is expected to deliver topline results this year. Unlike prior amyloid-targeting therapies requiring infusions, AR1001 is an oral drug designed to target toxic amyloid-beta oligomers, which would make it significantly more accessible if the data hold. The results could reshape early-stage cognitive decline treatment.
Read more →Supplements & Compounds
Krill Oil Reliably Cuts Triglycerides—But Leaves Cholesterol Untouched: What That Split Tells You About Your Own Response
Across multiple high-quality studies, krill oil consistently lowers blood triglycerides but barely moves LDL or HDL cholesterol—making it one of the few supplements where your personal response is directly measurable with a standard blood test. The evidence-backed protocol: 2–4 grams daily split with meals, then check triglycerides at 12 weeks. If they haven't dropped by at least 10 mg/dL, you're likely a non-responder—and no amount of higher dosing or extended use changes that.
Read the full Aviado analysis →GLP-1 Drugs Created a Supplement Category Almost Overnight—Here's Where the Evidence Actually Stands
The explosion of GLP-1 medications like semaglutide has spawned an entirely new supplement category of "GLP-1 support" products—but the gap between marketing claims and actual evidence is wide. Nutritional Outlook breaks down the science behind these products, what mechanisms are plausibly supported, and where manufacturers are outrunning the data. Worth reading before spending money on any product claiming to boost GLP-1 activity naturally.
Read more →Research & Papers
Could GLP-1 Drugs Like Ozempic Actually Slow Biological Aging?
A small study in people with HIV and lipohypertrophy found that eight months of semaglutide appeared to slow biological aging as measured by blood-based age-related biomarkers—adding to a growing case that GLP-1 drugs may do far more than manage weight and blood sugar. Caveats apply: the study involved a specific population, so generalizability is limited, and biological age clocks remain imperfect proxies. Still, the signal is intriguing enough that the NYT devoted a full reported piece to it.
Read more →A Newly Discovered Reason Your Cells' Power Stations Fade With Age—And a Potential Fix
Scientists have identified a reduction in phosphatidylcholine—a lipid critical to mitochondrial membrane integrity—as a significant contributor to the energy decline that accompanies aging. While not the sole cause of mitochondrial dysfunction, this specific deficiency is now a validated target that researchers are actively investigating. Phosphatidylcholine is available as a supplement; it's too early to say supplementation reverses this specific aging mechanism, but the mechanistic pathway is now considerably clearer.
Read more →Gut Metabolite TMAO Drives Bone-Cell Aging—Adding Mechanistic Weight to the Diet-Bone Connection
A new study in Calcified Tissue International finds that TMAO—a compound produced when gut bacteria metabolize red meat and eggs—induces cellular senescence in osteoblasts and impairs bone formation via the cGAS-STING-NF-κB signaling axis. In mice, chronic TMAO exposure visibly damaged bone microarchitecture; silencing the STING gene partially reversed this damage. This is preclinical research (cell and mouse data), but it adds mechanistic weight to the dietary pattern that health-focused consumers already associate with cardiovascular risk—now with a bone health dimension worth watching.
Read more →Lifestyle & Nutrition
The Weekly Strength Training Dose That Slashes Mortality Risk: 90 Minutes Is Enough
A Harvard T.H. Chan School of Public Health analysis published in Sports Medicine found that just 90–119 minutes of weekly resistance training reduces all-cause mortality by 13%, cardiovascular death by 19%, and neurological death by 27%. That's under two hours a week—achievable for most people with two solid sessions. The finding reinforces that the longevity dividend from strength training doesn't require extreme volume; it requires showing up consistently at a moderate dose.
Read more →Industry & Policy
Bausch + Lomb's Eye Health Supplement Hits Significant Markers in Clinical Dry Eye Trial
Bausch + Lomb's NutriTears daily nutritional supplement produced statistically significant improvements in corneal and conjunctival staining (p<0.001) and reductions in MMP-9 inflammation markers by day 56 in a new clinical study. Notably, the trial used objective biomarker endpoints rather than self-reported symptom relief—a higher bar. Dry eye disease affects hundreds of millions globally and is increasingly understood as inflammation-driven; an evidence-backed nutritional option could meaningfully complement or reduce reliance on prescription drops.
Read more →